CAM
CRSP icon

Costello Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Costello Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7K Hold
600
– – 0.01% 324
2026
Q1 		$28.5K Hold
600
– – 0.01% 325
2025
Q4 		$31.5K Sell
600
-200
-25% -$12K 0.01% 305
2025
Q3 		$51.8K Hold
800
– – 0.02% 233
2025
Q2 		$38.9K Hold
800
– – 0.01% 272
2025
Q1 		$27.2K Buy
+800
New +$33.9K 0.01% 308

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Costello Asset Management's CRSP Position: Q2 2026 in Review

Costello Asset Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 600 shares worth $32.7K. The position accounts for 0.01% of the portfolio, ranked #324.

Costello Asset Management first reported a position in CRSP in Q1 2025 and has held it in 6 quarters since. The position peaked at $51.8K in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Costello Asset Management held 600 shares of CRISPR Therapeutics worth $32.7K as of Q2 2026.
  • Costello Asset Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Costello Asset Management's portfolio in Q2 2026, its #324 holding.
  • Costello Asset Management first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Costello Asset Management's CRISPR Therapeutics position peaked at $51.8K in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Costello Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.